Calquence 100mg Capsule

About

Calquence 100mg Capsule contains acalabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This targeted therapy is used to treat certain types of B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). Acalabrutinib works by selectively binding to and inhibiting BTK, a protein crucial for the survival and proliferation of malignant B-cells. By blocking BTK, Calquence disrupts the signaling pathways that drive cancer cell growth, leading to their apoptosis and reduced tumor burden. It represents a significant advancement in the treatment of these cancers, offering an effective option for patients who may have relapsed or are refractory to other therapies, or as a first-line treatment.

Uses

• Chronic lymphocytic leukemia (CLL)
• Small lymphocytic lymphoma (SLL)
• Mantle cell lymphoma (MCL)
• Relapsed or refractory CLL/SLL

Directions For Use

Take one capsule orally twice daily, approximately 12 hours apart, with or without food.

Benefits

• Highly targeted anti-cancer action
• Effective in resistant forms of leukemia/lymphoma
• Improves progression-free survival
• Reduces tumor burden effectively
• Convenient oral administration
• Generally well-tolerated compared to chemotherapy

Side Effects

• Headache
• Diarrhea
• Fatigue
• Muscle pain (myalgia)
• Bruising
• Rash
• Nausea
• Anemia
• Neutropenia
• Thrombocytopenia
• Hypertension
• Atrial fibrillation

Safety Measures

• Alcohol - No specific interaction, but moderation is advised. Consult your doctor regarding alcohol consumption.
• Pregnancy - Calquence may cause fetal harm and should be avoided during pregnancy. Effective contraception is required for women of childbearing potential.
• Breastfeeding - It is unknown if acalabrutinib is excreted in human milk. Due to potential serious adverse reactions, breastfeeding is not recommended.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustments may be necessary for severe liver dysfunction.
• Kidney - No dose adjustment is typically required for mild to moderate renal impairment. Use with caution in severe impairment.
• Lung - Monitor for new or worsening respiratory symptoms, as interstitial lung disease has been reported rarely.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.